source
- Leqembi posts $184M Q2 sales, best quarter since launch, Biogen lifts guidanceLeqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen. The Q2 figure represents the stronge…
- Teva says it has time to prepare for upcoming US tariffs on imported generic drugsTeva CEO Richard Francis said the company believes it has sufficient time to prepare for the tariffs the Trump administration is considering on generic drugs imported from outside the United States…